FMR funds sell 17,452 Structure Therapeutics ADSs

FMR LLC, a ten percent owner of Structure Therapeutics Inc., reported open-market sales of American Depositary Shares (ADSs) of GPCR.

Rhea-AI Filing Summary

FMR LLC, a ten percent owner of Structure Therapeutics Inc., reported open-market sales of American Depositary Shares (ADSs) of GPCR. Funds associated with FMR LLC sold 1,367 ADSs and 16,085 ADSs on April 14, 2026 at a weighted average price of $55.07 per ADS in separate transactions.

Each ADS represents three ordinary shares of Structure Therapeutics. After these sales, F-Prime Capital Partners Life Sciences Advisors Fund VI LP held 2,736 ADSs, and F-Prime Capital Partners Life Sciences Fund VI LP held 32,171 ADSs. A larger indirect position remains through ADSs representing 4,546,674 underlying ordinary shares.

Insider Trade Summary

Net Seller: 17,452 shares

Net Sell 5 txns

Insider FMR LLC

Role 10% Owner

Sold 17,452 shs ($961K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares	1,367	$55.07	$75K
Sale	American Depositary Shares	16,085	$55.07	$886K
holding	American Depositary Shares	--	--	--
holding	Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: American Depositary Shares — 2,736 contracts (Indirect, F-Prime Capital Partners Life Sciences Advisors Fund VI LP); American Depositary Shares — 32,171 contracts (Indirect, F-Prime Capital Partners Life Sciences Fund VI LP); American Depositary Shares — 4,546,674 contracts (Indirect, Shares held by persons and entities whose shares are subject to reporting by the undersigned); Ordinary Shares — 20,502 shares (Indirect, F-Prime Capital Partners Life Sciences Advisors Fund VI LP); Ordinary Shares — 241,275 shares (Indirect, F-Prime Capital Partners Life Sciences Fund VI LP)

Footnotes (2)

1. F1. Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer.
2. F2. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $55.00 to $55.20. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.

Key Figures

ADS sold by Advisors Fund VI: 1,367 ADSs at $55.07 ADS sold by Fund VI: 16,085 ADSs at $55.07 Total ADSs sold: 17,452 ADSs +4 more

7 metrics

ADS sold by Advisors Fund VI 1,367 ADSs at $55.07 Open-market sale on April 14, 2026

ADS sold by Fund VI 16,085 ADSs at $55.07 Open-market sale on April 14, 2026

Total ADSs sold 17,452 ADSs Net open-market sales reported in Form 4

Advisors Fund VI ADS holdings 2,736 ADSs Indirect holdings after transactions on April 14, 2026

Fund VI ADS holdings 32,171 ADSs Indirect holdings after transactions on April 14, 2026

Underlying ordinary shares via ADSs 4,546,674 ordinary shares Indirect position represented by ADSs

ADS to ordinary share ratio 1 ADS : 3 ordinary shares Representation of Structure Therapeutics ordinary shares

Key Terms

American Depositary Shares, ten percent owner, open-market sale, weighted average price, +1 more

5 terms

American Depositary Shares financial

"Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

ten percent owner financial

"FMR LLC is indicated as a ten percent owner of Structure Therapeutics Inc."

open-market sale financial

"Transactions are coded as S and described as an open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average price financial

"The price reported for this transaction is the weighted average price of multiple trades"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

indirect ownership financial

"Holdings are reported as indirect with nature of ownership attributed to F-Prime Capital funds"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did FMR LLC report for Structure Therapeutics (GPCR)?

FMR LLC reported that affiliated funds sold a total of 17,452 American Depositary Shares of Structure Therapeutics on April 14, 2026. These were open-market sales at a weighted average price of $55.07 per ADS, as disclosed in the Form 4 filing.

At what price were the GPCR American Depositary Shares sold by FMR-linked funds?

The ADSs of Structure Therapeutics linked to FMR LLC were sold at a weighted average price of $55.07 per share. The filing notes multiple trades occurred in a range from $55.00 to $55.20, which together produced the reported average sale price.

How many GPCR ADSs did F-Prime Capital funds sell and how much do they still hold?

F-Prime Capital Partners Life Sciences Advisors Fund VI LP sold 1,367 ADSs and now holds 2,736 ADSs. F-Prime Capital Partners Life Sciences Fund VI LP sold 16,085 ADSs and now holds 32,171 ADSs, all reported as indirect holdings in the Form 4.

What does each Structure Therapeutics (GPCR) ADS represent in ordinary shares?

Each American Depositary Share of Structure Therapeutics represents three underlying ordinary shares of the issuer. This ratio is explicitly stated in the Form 4 footnotes and helps investors translate ADS positions into the company’s ordinary share equivalent.

How large is FMR LLC’s remaining indirect economic exposure to Structure Therapeutics?

The filing shows an indirect position of ADSs representing 4,546,674 underlying ordinary shares. This figure reflects a substantial remaining exposure to Structure Therapeutics, even after the reported open-market sales of 17,452 ADSs by F-Prime Capital-related funds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/16/2026 - 02:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FMR LLC

(Last) (First) (Middle)

245 SUMMER STREET

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remark 1

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares								20,502	I	F-Prime Capital Partners Life Sciences Advisors Fund VI LP
Ordinary Shares								241,275	I	F-Prime Capital Partners Life Sciences Fund VI LP

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	(1)							(1)	(1)	Ordinary Shares	4,546,674		1,515,558	I	Shares held by persons and entities whose shares are subject to reporting by the undersigned
American Depositary Shares	(1)	04/14/2026		S			1,367	(1)	(1)	Ordinary Shares	4,101	$55.07(2)	2,736	I	F-Prime Capital Partners Life Sciences Advisors Fund VI LP
American Depositary Shares	(1)	04/14/2026		S			16,085	(1)	(1)	Ordinary Shares	48,255	$55.07(2)	32,171	I	F-Prime Capital Partners Life Sciences Fund VI LP

Explanation of Responses:

1. Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer.

2. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $55.00 to $55.20. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VI LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VI LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.

	/s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)